

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF BOARD COMMITTEES

PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

On 11 January 2019, the board (the **“Board”**) of directors (the **“Director(s)”**) of Sinopharm Group Co. Ltd. (the **“Company”**) resolved to propose to appoint Ms. Guan Xiaohui (**“Ms. Guan”**) as a non-executive Director and a member of the audit committee of the Board (the **“Audit Committee”**).

In accordance with the articles of association of the Company, the proposed appointment of Ms. Guan as non-executive Director is subject to the approval by the shareholders of the Company (the **“Shareholders”**) at a general meeting of the Company. The term of office of Ms. Guan as non-executive Director will take effect from the date of approval by the Shareholders at the general meeting of the Company and until the expiration of the term of the current session of the Board. Ms. Guan's position as a member of the Audit Committee will take effect upon the approval of her appointment as a non-executive Director by the Shareholders at the general meeting of the Company.

Biographical details of Ms. Guan Xiaohui:

Ms. Guan Xiaohui (關曉暉), aged 47, joined Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (**“Fosun Pharma”**), a company listed on The Stock Exchange of Hong Kong Limited (the **“Hong Kong Stock Exchange”**, stock code: 02196) in May 2000 and currently serves as the Senior Vice President and Chief Financial Officer of Fosun Pharma. Ms. Guan obtained a bachelor's degree in Economics from Jiangxi University of Finance and Economics and obtained a master's degree in Accounting for senior accountant from the Chinese University of Hong Kong in December 2007. Before joining Fosun Pharma and its subsidiaries, Ms. Guan worked at Jiangxi Provincial Branch of the Industrial and Commercial Bank of China from July 1992 to May 2000. Ms. Guan served as the supervisor of China National Accord

Medicines Corporation Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000028) and the supervisor of BioSino Bio-Technology and Science Incorporation (a company listed on the Hong Kong Stock Exchange, stock code: 08247). Mr. Guan is qualified as Chinese Certified Public Accountant and a member of The Association of Chartered Certified Accountants.

Save as disclosed above and as at the date of this announcement, Ms. Guan does not have any relationships with any Directors, senior management, substantial or controlling shareholder(s) of the Company, or holds any other positions in the Company or any of its subsidiaries, or any directorships in other listed companies in the last three years.

As at the date of this announcement, Ms. Guan does not have any interest in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Upon due appointment as Director, Ms. Guan will enter into a service contract with the Company for a term commencing from the date of appointment and ending on the expiration of the term of the current session of the Board. Pursuant to the articles of association of the Company, Ms. Guan will be subject to retirement by rotation and re-election upon the expiry of her term of office.

The remuneration package of Ms. Guan will be determined by the Board as authorized by the Shareholders at a general meeting of the Company by taking into account, among other matters, her duties and responsibilities in the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Ms. Guan as non-executive Director that need to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

A notice of extraordinary general meeting of the Company containing, among others, detailed information of the above-mentioned proposal will be despatched to the Shareholders in due course.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that with effect from 11 January 2019, Mr. Wen Deyong, a non-executive Director, was appointed as a member of the remuneration committee of the Board and a member of the strategy and investment committee of the Board.

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
11 January 2019

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong and Mr. Wen Deyong; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*